Ypsomed Holding Future Growth
Future criteria checks 2/6
Ypsomed Holding is forecast to grow earnings and revenue by 5.2% and 8.5% per annum respectively. EPS is expected to grow by 5.7% per annum. Return on equity is forecast to be 19.9% in 3 years.
Key information
5.2%
Earnings growth rate
5.69%
EPS growth rate
| Medical Equipment earnings growth | 15.7% |
| Revenue growth rate | 8.5% |
| Future return on equity | 19.90% |
| Analyst coverage | Good |
| Last updated | 08 Jun 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jun 06
YPSN: Cautious Outlook As Medium Term Sales Face New Headwinds
Analysts have adjusted their blended fair value estimate for Ypsomed Holding from about CHF 309.85 to roughly CHF 301.03, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions in light of mixed new coverage and concerns around Cagrisema exposure. Analyst Commentary Recent Street research around Ypsomed Holding shows a split view, with some firms initiating or upgrading with a more constructive stance and others highlighting meaningful risks tied to Cagrisema exposure and the company’s medium term growth profile.Analysis Article • May 28
We Think You Should Be Aware Of Some Concerning Factors In Ypsomed Holding's (VTX:YPSN) Earnings
The market for Ypsomed Holding AG's ( VTX:YPSN ) stock was strong after it released a healthy earnings report last...Analysis Article • May 23
Earnings Beat: Ypsomed Holding AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Ypsomed Holding AG ( VTX:YPSN ) just released its yearly report and things are looking bullish. The company beat...
Narrative Update • May 21
YPSN: Recent Share Buyback And Bank Upgrades Will Support Future Upside
Analysts have trimmed their price target on Ypsomed Holding to about CHF 388 from roughly CHF 399, reflecting updated views on slightly lower long term fair value and modestly softer assumptions for revenue growth, profit margins and future P/E, even as recent bullish initiations and upgrades from major banks support a generally positive stance on the stock. Analyst Commentary Bullish Takeaways Bullish analysts highlight recent initiations and upgrades as support for the current valuation reset, suggesting that the trimmed price target still sits within a range they view as justified by the company’s positioning.Narrative Update • May 01
YPSN: Share Buyback And Recent Upgrade Will Support Long Term Upside
Analysts have slightly adjusted their view on Ypsomed Holding, trimming the fair value estimate from CHF 314.70 to CHF 309.85 as they factor in updated assumptions for discount rates, revenue growth, profit margins and future P/E, reflected in part by a recent upgrade from Barclays. Analyst Commentary Even with the fair value estimate only slightly adjusted, some readers may want to pay close attention to where analysts see potential pressure on the story, especially around valuation and execution against expectations.Narrative Update • Apr 17
YPSN: Share Buyback And Injection Partnership Will Support Future Upside Potential
Analysts have trimmed their price target for Ypsomed Holding slightly to CHF 399.20 from CHF 403.00, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Board of Directors authorized a share buyback plan on February 27, 2026, establishing the framework for repurchases under a defined program (company announcement).Narrative Update • Apr 03
YPSN: Share Buyback Will Support Bullish Long Term Outlook
Analysts have reduced their price target for Ypsomed Holding from CHF 359.75 to CHF 314.70. This reflects updated views on fair value, a slightly higher discount rate, marginally adjusted revenue growth assumptions, a lower profit margin outlook and a lower future P/E multiple.
Narrative Update • Mar 20
YPSN: Share Buyback And Large-Volume Injection Partnership Will Drive Upside
Analysts have kept their CHF 475 price target for Ypsomed Holding unchanged, citing slightly adjusted assumptions for the discount rate, revenue growth and profit margin, while maintaining a broadly similar outlook for the future P/E ratio. What's in the News On February 27, 2026, the Board of Directors authorized a share buyback plan for Ypsomed Holding and set the framework for repurchases.Narrative Update • Mar 05
YPSN: Large Volume Injection Collaboration Will Support Future Earnings Resilience
Analysts have trimmed their price target for Ypsomed Holding slightly, from CHF 407.44 to CHF 403.00. This reflects modest adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Narrative Update • Feb 19
YPSN: Large Volume Injection Partnership Will Support Future Earnings Resilience
Analysts have kept their CHF price target for Ypsomed Holding broadly unchanged at around CHF 407, as only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions were applied in their latest models. What's in the News BD and Ypsomed Holding are expanding their collaboration to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe that is designed to be fully compatible with Ypsomed's YpsoMate 5.5 autoinjector platform, targeting large volume subcutaneous self injections for biologic drugs.Narrative Update • Feb 05
YPSN: Large Volume Autoinjector Partnership Will Drive Medium-Term Upside
Analysts are maintaining their price target for Ypsomed Holding at CHF 475.00. The steady view reflects updated assumptions around revenue growth, profit margins and the future P/E, which largely offset the modest adjustment in the discount rate.Narrative Update • Jan 22
YPSN: Large Volume Self Injection Platform Will Support Future Earnings Resilience
Analysts have trimmed their price target for Ypsomed Holding slightly to CHF 407.44 from CHF 407.78, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that marginally adjust their valuation model. What's in the News BD and Ypsomed are working together on a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe that is intended to be fully compatible with Ypsomed's YpsoMate 5.5 autoinjector platform, targeting large volume subcutaneous self injections for biologic medicines.Analysis Article • Jan 20
Ypsomed Holding AG's (VTX:YPSN) Business Is Yet to Catch Up With Its Share Price
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...Narrative Update • Jan 08
YPSN: Drug Delivery Pipeline And Capacity Expansion Will Drive Medium-Term Upside
Analysts have maintained their price target for Ypsomed Holding at CHF 475.00. The latest update reflects only slight adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E, rather than a change in their overall view.Analysis Article • Jan 07
Here's Why We Think Ypsomed Holding (VTX:YPSN) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Dec 19
Ypsomed Holding (VTX:YPSN) Is Investing Its Capital With Increasing Efficiency
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Narrative Update • Dec 18
YPSN: Drug Delivery Pipeline And Capacity Expansion Will Drive Medium-Term Upside
Analysts have lowered their price target on Ypsomed Holding from CHF 525 to CHF 475. This reflects more cautious assumptions on revenue growth, profitability and valuation multiples in light of a recently reinstated Underperform rating on the stock.Narrative Update • Dec 04
YPSN: Long Term Injectable Demand Will Support Future Earnings Resilience
Analysts made a modest downward adjustment to their price target on Ypsomed Holding, trimming fair value expectations from roughly CHF 409 to CHF 408 as they factor in slightly higher discount rates and a more cautious stance following the recent Underperform rating reinstatement, even though revenue growth and profit margin forecasts have been revised slightly upward. Analyst Commentary Analysts see a mixed risk reward profile for Ypsomed, with some acknowledging solid fundamentals and long term structural demand for drug delivery solutions, while others emphasize valuation pressure and execution risks that they believe justify a more cautious stance.Narrative Update • Nov 20
YPSN: Market Demand For Injectables Will Support Future Earnings Momentum
Analysts have trimmed their fair value estimate for Ypsomed Holding to CHF 408.92 from CHF 421.59. They cited a slightly lower discount rate, upward revisions to expected revenue growth and profit margin, as well as a more conservative market outlook reflected in recent Street research.Analysis Article • Nov 17
When Should You Buy Ypsomed Holding AG (VTX:YPSN)?
Ypsomed Holding AG ( VTX:YPSN ), is not the largest company out there, but it received a lot of attention from a...Narrative Update • Nov 06
YPSN: Demand for Injectables Will Drive Future Earnings and Market Performance
Analysts have made no change to Ypsomed Holding’s fair value target, maintaining it at CHF 421.59. Recent research highlights both strong growth prospects in the injectables market and mixed sentiment following recent coverage changes.Narrative Update • Oct 22
Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins
The analyst consensus price target for Ypsomed Holding has been revised downward by CHF 8.33 to CHF 421.59, as analysts cite slightly moderated growth prospects and profit margins. This comes despite continued optimism about the company's leadership in the high-growth injectables market.Analysis Article • Oct 18
Ypsomed Holding AG's (VTX:YPSN) Share Price Is Still Matching Investor Opinion Despite 25% Slump
The Ypsomed Holding AG ( VTX:YPSN ) share price has fared very poorly over the last month, falling by a substantial...Narrative Update • Oct 08
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Analysts have lowered their fair value estimate for Ypsomed Holding from CHF 449.37 to CHF 429.92. They cite a more cautious outlook due to softer revenue growth expectations and increased discount rates, despite optimism about the company's leading role in the injectables market.Narrative Update • Sep 23
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Analyst sentiment on Ypsomed Holding has turned more cautious, citing diverging views on the sustainability of recent growth and transformation despite ongoing demand in injectables, resulting in a lowered consensus price target from CHF463.26 to CHF449.37. Analyst Commentary Bullish analysts highlight Ypsomed's leading position in the high-growth injectable market.Narrative Update • Sep 05
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Ypsomed Holding’s analyst price target has been revised upward to CHF463.26 as the company consolidates its leadership in the high-growth injectables market following strategic divestitures and a sharpened operational focus. Analyst Commentary The company has established a leadership position in the high-growth injectable market.Analysis Article • Aug 20
Ypsomed Holding (VTX:YPSN) Might Have The Makings Of A Multi-Bagger
SWX:YPSN 1 Year Share Price vs Fair Value Explore Ypsomed Holding's Fair Values from the Community and select yours To...Analysis Article • Aug 07
Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
SWX:YPSN 1 Year Share Price vs Fair Value Explore Ypsomed Holding's Fair Values from the Community and select yours...Analysis Article • Jul 24
We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jul 11
Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jun 11
Is Now An Opportune Moment To Examine Ypsomed Holding AG (VTX:YPSN)?
Ypsomed Holding AG ( VTX:YPSN ), is not the largest company out there, but it received a lot of attention from a...
New Narrative • Dec 07
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, enhancing margins and earnings.Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2029 | 899 | 235 | 171 | 332 | 8 |
| 3/31/2028 | 796 | 201 | 68 | 295 | 9 |
| 3/31/2027 | 701 | 179 | 30 | 307 | 9 |
| 3/31/2026 | 731 | 222 | -16 | 307 | N/A |
| 12/31/2025 | 759 | 208 | -45 | 259 | N/A |
| 9/30/2025 | 788 | 194 | -74 | 212 | N/A |
| 6/30/2025 | 768 | 141 | -101 | 180 | N/A |
| 3/31/2025 | 749 | 88 | -129 | 148 | N/A |
| 12/31/2024 | 683 | 81 | -108 | 152 | N/A |
| 9/30/2024 | 617 | 74 | -87 | 157 | N/A |
| 6/30/2024 | 583 | 76 | -59 | 160 | N/A |
| 3/31/2024 | 548 | 78 | -32 | 163 | N/A |
| 12/31/2023 | 529 | 75 | -37 | 148 | N/A |
| 9/30/2023 | 509 | 72 | -43 | 133 | N/A |
| 6/30/2023 | 503 | 62 | -41 | 131 | N/A |
| 3/31/2023 | 497 | 51 | -40 | 130 | N/A |
| 12/31/2022 | 492 | 41 | -37 | 118 | N/A |
| 9/30/2022 | 486 | 31 | -35 | 107 | N/A |
| 6/30/2022 | 476 | 27 | -38 | 97 | N/A |
| 3/31/2022 | 465 | 23 | -42 | 86 | N/A |
| 9/30/2021 | 427 | 6 | -28 | 90 | N/A |
| 6/30/2021 | 415 | 6 | -28 | 88 | N/A |
| 3/31/2021 | 404 | 6 | -28 | 86 | N/A |
| 9/30/2020 | 403 | 11 | -67 | 60 | N/A |
| 6/30/2020 | 399 | 11 | -69 | 54 | N/A |
| 3/31/2020 | 394 | 12 | -70 | 49 | N/A |
| 12/31/2019 | 390 | 12 | N/A | 44 | N/A |
| 9/30/2019 | 386 | 12 | N/A | 39 | N/A |
| 6/30/2019 | 420 | 36 | N/A | 49 | N/A |
| 3/31/2019 | 454 | 60 | N/A | 60 | N/A |
| 12/31/2018 | 483 | 72 | N/A | 68 | N/A |
| 9/30/2018 | 511 | 85 | N/A | 76 | N/A |
| 6/30/2018 | 489 | 68 | N/A | 65 | N/A |
| 3/31/2018 | 466 | 52 | N/A | 53 | N/A |
| 12/31/2017 | 442 | 50 | N/A | 62 | N/A |
| 9/30/2017 | 418 | 47 | N/A | 70 | N/A |
| 6/30/2017 | 404 | 47 | N/A | 73 | N/A |
| 3/31/2017 | 390 | 46 | N/A | 75 | N/A |
| 12/31/2016 | 377 | 45 | N/A | 77 | N/A |
| 9/30/2016 | 365 | 43 | N/A | 78 | N/A |
| 6/30/2016 | 351 | 39 | N/A | 78 | N/A |
| 3/31/2016 | 337 | 36 | N/A | 77 | N/A |
| 12/31/2015 | 326 | 31 | N/A | 61 | N/A |
| 9/30/2015 | 316 | 26 | N/A | 45 | N/A |
| 6/30/2015 | 311 | 22 | N/A | 43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YPSN's forecast earnings growth (5.2% per year) is above the savings rate (0.6%).
Earnings vs Market: YPSN's earnings (5.2% per year) are forecast to grow slower than the Swiss market (10.9% per year).
High Growth Earnings: YPSN's earnings are forecast to grow, but not significantly.
Revenue vs Market: YPSN's revenue (8.5% per year) is forecast to grow faster than the Swiss market (4.9% per year).
High Growth Revenue: YPSN's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YPSN's Return on Equity is forecast to be low in 3 years time (19.9%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 14:46 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ypsomed Holding AG is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |
| Gaurav Jain | Barclays |